---
title: "Top 5 港股千亿以上公司涨跌幅（8月29日）"
description: "药明生物 (02269) 涨 6.96%，成交额 27.3 亿港元，年内累计涨 89.1%。 信达生物 (01801) 涨 6.84%，成交额 25.4 亿港元，年内累计涨 164.6%。 顺丰控股 (06936) 跌 11.62%，成交额 15.2 亿港元，年内累计涨 20.2%。 中兴通讯 (00763) 跌 9.27%，成交额 25.2 亿港元，年内累计涨 47.9%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255150943.md"
published_at: "2025-08-29T08:30:51.000Z"
---

# Top 5 港股千亿以上公司涨跌幅（8月29日）

> 药明生物 (02269) 涨 6.96%，成交额 27.3 亿港元，年内累计涨 89.1%。 信达生物 (01801) 涨 6.84%，成交额 25.4 亿港元，年内累计涨 164.6%。 顺丰控股 (06936) 跌 11.62%，成交额 15.2 亿港元，年内累计涨 20.2%。 中兴通讯 (00763) 跌 9.27%，成交额 25.2 亿港元，年内累计涨 47.9%。

恒生指数涨 0.32%，年内累计涨 25%；恒生科技指数涨 0.54%，年内累计涨 27%。

药明生物 (02269) 涨 6.96%，成交额 27.3 亿港元，年内累计涨 89.1%。

信达生物 (01801) 涨 6.84%，成交额 25.4 亿港元，年内累计涨 164.6%。

顺丰控股 (06936) 跌 11.62%，成交额 15.2 亿港元，年内累计涨 20.2%。

中兴通讯 (00763) 跌 9.27%，成交额 25.2 亿港元，年内累计涨 47.9%。

### Related Stocks

- [02269.HK - 药明生物](https://longbridge.com/zh-CN/quote/02269.HK.md)
- [01801.HK - 信达生物](https://longbridge.com/zh-CN/quote/01801.HK.md)
- [01093.HK - 石药集团](https://longbridge.com/zh-CN/quote/01093.HK.md)
- [02359.HK - 药明康德](https://longbridge.com/zh-CN/quote/02359.HK.md)
- [01177.HK - 中国生物制药](https://longbridge.com/zh-CN/quote/01177.HK.md)
- [06936.HK - 顺丰控股](https://longbridge.com/zh-CN/quote/06936.HK.md)
- [00763.HK - 中兴通讯](https://longbridge.com/zh-CN/quote/00763.HK.md)
- [01919.HK - 中远海控](https://longbridge.com/zh-CN/quote/01919.HK.md)
- [06099.HK - 招商证券](https://longbridge.com/zh-CN/quote/06099.HK.md)
- [02388.HK - 中银香港](https://longbridge.com/zh-CN/quote/02388.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/275882948.md) |
| China's Innovent clinches new Lilly deal for immunology, cancer drug development | China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, i | [Link](https://longbridge.com/zh-CN/news/275255059.md) |
| Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug | [Link](https://longbridge.com/zh-CN/news/275387692.md) |
| WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink | WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not alr | [Link](https://longbridge.com/zh-CN/news/275670240.md) |
| Wuxi Biologics FY Revenue RMB21,790 Million | WuXi Biologics (Cayman) :FY REVENUE RMB 21,790 MILLIONFY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLIONFY ADJUSTED NON- | [Link](https://longbridge.com/zh-CN/news/275534123.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。